Midodrine or atomoxetine pill

PreclinicalSmall molecule

Midodrine or atomoxetine pill is one of 29 small molecule programs targeting Orthostatic Hypotension. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Orthostatic HypotensionActive, not recruiting

Orthostatic; Hypotension, NeurogenicRecruiting

Orthostatic HypotensionPreclinical

Active, not recruiting

Orthostatic; Hypotension, NeurogenicPreclinical

Recruiting

Competition

Competitive Landscape

40 competitors in Orthostatic Hypotension

#DrugCompanyPhaseTrials

Northera

Lundbeck

Approved

10 2

Proamatine

Takeda

Approved

6 3

Corlanor

Amgen

Approved

—4

Midodrine Hydrochloride

Takeda

Approved

4 5

Inderal

WWyeth-Lederle Vaccines

Approved

—6

Vivarin

HHikma Pharmaceuticals LLC

Mestinon

1 8

Midodrine Hcl

Mylan Pharmaceuticals Inc

Approved

3 9

Ritalin

Novartis

Phase 1

1 10

Diamox

Teva

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Orthostatic; Hypotension, Neurogenic

NCT04782830

Clinical

Trials by Indication[1]

Orthostatic; Hypotension, Neurogenic1 trial

Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms

Recruiting·VVanderbilt University Medical Center·Preclinical·NCT04782830·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Midodrine or atomoxetine pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Midodrine or atomoxetine pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Midodrine or atomoxetine pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VVanderbilt University Medical Center

Midodrine or atomoxetine pill

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Orthostatic; Hypotension, Neurogenic1 trial

References

Drug Info

Quick Facts

Related News